ClearBridge Investments
PTGX icon

ClearBridge Investments’s Protagonist Therapeutics PTGX Stock Holding History

ClearBridge Investments’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.9M Buy
725,335
+103,515
+17% +$10.8M 0.07% 243
2026
Q1 		$65.5M Buy
621,820
+131,978
+27% +$11.7M 0.06% 275
2025
Q4 		$42.8M Buy
+489,842
New +$40.1M 0.03% 349

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

ClearBridge Investments's PTGX Position: Q2 2026 in Review

ClearBridge Investments increased its Protagonist Therapeutics (PTGX) stake by 17% in Q2 2026, buying an estimated $10.8M and bringing the position to 725,335 shares worth $88.9M. The position accounts for 0.07% of the portfolio, ranked #243.

ClearBridge Investments first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • ClearBridge Investments held 725,335 shares of Protagonist Therapeutics worth $88.9M as of Q2 2026.
  • ClearBridge Investments bought 103,515 Protagonist Therapeutics shares in Q2 2026, an estimated $10.8M.
  • Protagonist Therapeutics made up 0.07% of ClearBridge Investments's portfolio in Q2 2026, its #243 holding.
  • ClearBridge Investments first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on ClearBridge Investments's 13F filing for Q2 2026, filed 13 Aug 2026.